共查询到20条相似文献,搜索用时 31 毫秒
1.
2.
3.
Laura A. Dawson Kathryn A. Winter Alan W. Katz Michael C. Schell James Brierley Yuhchyau Chen Neil Kopek Christopher H. Crane Christopher G. Willett 《Practical radiation oncology》2019,9(4):e386-e393
PurposeThis study aimed to determine the feasibility and maximally tolerated dose of hypofractionated, conformal radiation therapy (RT) in patients with liver metastases.Methods and materialsNonsurgical patients with ≤5 liver metastases (sum of maximal diameter of all lesions ≤8 cm) were included in the study. There were 4 dose levels: 35 Gy, 40 Gy (starting level), 45 Gy, and 50 Gy, in 10 fractions. The clinical target volume included metastases identified on contrast computed tomography or magnetic resonance imaging with a 5-mm margin within the liver. The planning target volume margin ranged from 4 to 30 mm, depending on breathing motion. Dose-limiting toxicities were defined as RT-related grade ≥4 hepatic or gastrointestinal toxicities or thrombocytopenia occurring within 90 days of the start of RT.ResultsA total of 26 patients with metastases from colorectal (8 patients), breast (7 patients) and other malignancies (11 patients) were enrolled between November 2005 and December 2010. Twenty-three patients were evaluable (8, 7, and 8 on the 40, 45, and 50 Gy dose levels, respectively). Two patients assigned to 50 Gy received 35 Gy owing to normal tissue limits, so 2 additional patients were treated to 50 Gy. There were no dose-limiting toxicities on any of the dose levels. On the 45 Gy dose level, 1 patient developed reversible grade 3 enteritis (37 days from RT start) and diarrhea (22 days); another patient developed grade 3 lymphopenia (23 days). At the 50 Gy dose level, 1 patient had grade 3 hyperglycemia (74 days), and another patient developed grade 3 lymphopenia (13 days), colonic hemorrhage (325 days), and colonic gastrointestinal obstruction (325 days). With a potential median follow-up of 66.1 months (range, 34.6-89.0 months), no other late toxicities were observed.ConclusionsTreatment of liver metastases with 50 Gy in 10 fractions was feasible and safe in a multi-institutional setting. 相似文献
4.
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Vasu Divi MD Jonathan Harris MS Paul M. Harari MD Jay S. Cooper MD Jonathan McHugh MD Diana Bell MD Erich M. Sturgis MD Anthony J. Cmelak MD Mohan Suntharalingam MD David Raben MD Harold Kim MD Sharon A. Spencer MD George E. Laramore MD Andy Trotti MD Robert L. Foote MD Christopher Schultz MD Wade L. Thorstad MD Qiang Zhang PhD Quynh Thu Le MD F. Christopher Holsinger MD 《Cancer》2016,122(22):3464-3471
5.
Marsha Reyngold Kathryn A. Winter William F. Regine Ross A. Abrams Howard Safran John P. Hoffman Rex B. Mowat John P. Hayes Ivan L. Kessel Thomas DiPetrillo Samir Narayan Yuhchyau Chen Edgar Ben-Josef Guila Delouya John H. Suh Joshua Meyer Michael G. Haddock Marvin Feldman Rakesh Gaur Kathleen Yost Richard A. Peterson David L. Sherr Jennifer Moughan Christopher H. Crane 《The oncologist》2020,25(3):e477-e483
6.
Patil Nirav Somasundaram Eashwar Waite Kristin A. Lathia Justin D. Machtay Mitchell Gilbert Mark R. Connor James R. Rubin Joshua B. Berens Michael E. Buerki Robin A. Choi Serah Sloan Andrew E. Penas-Prado Marta Ashby Lynn S. Blumenthal Deborah T. Werner-Wasik Maria Hunter Grant K. Flickinger John C. Wendland Merideth M. Panet-Raymond Valerie Robins H. Ian Pugh Stephanie L. Mehta Minesh P. Barnholtz-Sloan Jill S. 《Journal of neuro-oncology》2021,155(3):363-372
Journal of Neuro-Oncology - Glioblastoma (GBM) is the most common primary malignant brain tumor. Sex has been shown to be an important prognostic factor for GBM. The purpose of this study was to... 相似文献
7.
Jessica S. Wells Stephanie Pugh Karan Boparai Jessica Rearden Katherine A. Yeager Deborah W. Bruner 《Journal of cancer education》2017,32(4):721-727
Despite initiatives to increase the enrollment of racial and ethnic minorities into cancer clinical trials in the National Cancer Institute National Cancer Clinical Trials Network (NCCTN), participation by Latino and African American populations remain low. The primary aims of this pilot study are (1) to develop a Cultural Competency and Recruitment Training Program (CCRTP) for physician investigators and clinical research associates (CRAs), (2) to determine if the CCRTP increases cultural competency scores among physician investigators and CRAs, and (3) to determine the impact of the CCRTP on minority patient recruitment into NRG Oncology Radiation Therapy Oncology Group (RTOG) clinical trials. Sixty-seven CRAs and physicians participated in an in-person or online 4-h CRRTP training. Five knowledge and attitude items showed significant improvements from pre- to post-training. A comparison between enrolling sites that did and did not participate in the CCRTP demonstrated a pre to 1-year post-incremental increase in minority accrual to clinical trials of 1.2 % among participating sites. While not statistically significant, this increase translated into an additional 300 minority patients accrued to NCCTN clinical trials in the year following the training from those sites who participated in the training. 相似文献
8.
Chip Caine Snehal Deshmukh Vinai Gondi Minesh Mehta Wolfgang Tomé Benjamin W. Corn Andrew Kanner Howard Rowley Vijayananda Kundapur Albert DeNittis Jeffrey Noah Greenspoon Andre A. Konski Glenn S. Bauman Adam Raben Wenyin Shi Merideth Wendland Lisa Kachnic 《Journal of neuro-oncology》2016,126(2):327-336
9.
10.
Jeffrey S Wefel Terri S Armstrong Stephanie L Pugh Mark R Gilbert Merideth M Wendland David G Brachman Kevin S Roof Paul D Brown Ian R Crocker H Ian Robins Grant Hunter Minhee Won Minesh P Mehta 《Neuro-oncology》2021,23(7):1125
BackgroundResults of NRG Oncology RTOG 0825 reported adding bevacizumab to standard chemoradiation did not significantly improve survival endpoints and resulted in greater decline in neurocognitive function (NCF) and patient-reported outcomes (PRO) over time in bevacizumab-treated patients. The present report provides additional results of patient-centered outcomes over time and their prognostic association with survival endpoints.MethodsNCF tests, MD Anderson Symptom Inventory - Brain Tumor Module (MDASI-BT), and European Organization for Research and Treatment of Cancer (EORTC) quality of life (QOL) questionnaire with brain cancer module (QLQ-C30/BN20) were completed in a subset of progression-free patients at baseline and longitudinally. The prognostic value of baseline and early changes in NCF and PROs and differences between treatments from baseline to follow-up assessments were evaluated.ResultsA total of 508 randomized patients participated. Baseline/early changes in NCF and PROs were prognostic for OS and PFS. No between-arm differences in time to deterioration were found. At week 6, patients treated with bevacizumab evidenced greater improvement on NCF tests of executive function and the MDASI-BT Cognitive Function scale, but simultaneously reported greater decline on the EORTC Cognitive Function Scale. At later time points (weeks 22, 34, and 46), patients treated with bevacizumab had greater worsening on NCF tests as well as PRO measures of cognitive, communication, social function, motor symptoms, general symptoms, and interference.ConclusionThe collection of patient-centered clinical outcome assessments in this phase III trial revealed greater deterioration in NCF, symptoms, and QOL in patients treated with bevacizumab. Baseline and early change in NCF and PROs were prognostic for survival endpoints. 相似文献
11.
Eudocia Q. Lee MD Peixin Zhang PhD Patrick Y. Wen MD Elizabeth R. Gerstner MD David A. Reardon MD Kenneth D. Aldape MD John F. deGroot MD Edward Pan MD Jeffrey J. Raizer MD Lyndon J. Kim MD Steven J. Chmura MD H. Ian Robins MD Jennifer M. Connelly MD James D. Battiste MD John L. Villano MD Naveed Wagle MD Ryan T. Merrell MD Merideth M. Wendland MD Minesh P. Mehta MD 《Cancer》2020,126(12):2821-2828
12.
13.
Danielle S. Bitterman Kathryn A. Winter Theodore S. Hong Charles S. Fuchs William F. Regine Ross A. Abrams Howard Safran John P. Hoffman Al B. Benson Timothy Kasunic Mary Mulcahy James F. Strauss Thomas DiPetrillo Philip J. Stella Yuhchyau Chen John P. Plastaras Christopher H. Crane 《International journal of radiation oncology, biology, physics》2021,109(1):201-211
14.
William Small Walter R. Bosch Mathew M. Harkenrider Jonathan B. Strauss Nadeem Abu-Rustum Kevin V. Albuquerque Sushil Beriwal Carien L. Creutzberg Patricia J. Eifel Beth A. Erickson Anthony W. Fyles Courtney L. Hentz Anuja Jhingran Ann H. Klopp Charles A. Kunos Loren K. Mell Lorraine Portelance Melanie E. Powell David K. Gaffney 《International journal of radiation oncology, biology, physics》2021,109(2):413-424
15.
16.
17.
Mack Roach Jennifer Moughan Colleen A F Lawton Adam P Dicker Kenneth L Zeitzer Elizabeth M Gore Young Kwok Michael J Seider I-Chow Hsu Alan C Hartford Eric M Horwitz Kosj Yamoah Christopher U Jones Jeff M Michalski W Robert Lee Thomas M Pisansky Rachel Rabinovitch Marvin Rotman Howard M Sandler 《The lancet oncology》2018,19(11):1504-1515
18.
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity‐modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer
下载免费PDF全文
![点击此处可从《Cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Akila N. Viswanathan MD MPH Jennifer Moughan MS Brigitte E. Miller MD Ying Xiao PhD Anuja Jhingran MD Lorraine Portelance MD Walter R. Bosch DSc Ursula A. Matulonis MD Neil S. Horowitz MD Robert S. Mannel MD Luis Souhami MD Beth A. Erickson MD Kathryn A. Winter MS William Small MD Jr David K. Gaffney MD PhD 《Cancer》2015,121(13):2156-2163
19.
《Journal of thoracic oncology》2017,12(2):368-374
IntroductionThe impact of selective surgical resection for patients with esophageal cancer treated with definitive chemoradiation has not been clearly evaluated long-term.MethodsNRG (National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, Gynecologic Oncology Group) Oncology Radiation Therapy Oncology Group 0246 was a multi-institutional, single-arm, open-label, nonrandomized phase II study that enrolled 43 patients from September 2003 to March 2008 with clinical stage T1–4N0–1M0 squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction from 19 sites. Patients received induction chemotherapy with fluorouracil (650 mg/m2/d), cisplatin (15 mg/m2/d), and paclitaxel (200 mg/m2/d) for two cycles followed by concurrent chemoradiation consisting of 50.4 Gy of radiation (1.8 Gy per fraction) and daily fluorouracil (300 mg/m2/d) with cisplatin (15 mg/m2/d) over the first 5 days. After definitive chemoradiation, patients were evaluated for residual disease. Selective esophagectomy was considered only for patients with residual disease after chemoradiation (clinical incomplete response) or recurrent disease on surveillance.ResultsThis report looks at the long-term outcome of this selective surgical strategy. With a median follow-up of 8.1 years (minimum to maximum for 12 alive patients 7.2–9.8 years), the estimated 5- and 7-year survival rates are 36.6% (95% confidence interval [CI]: 22.3–51.0) and 31.7% (95% CI: 18.3–46.0). Clinical complete response was achieved in 15 patients (37%), with 5- and 7-yearr survival rates of 53.3% (95% CI: 26.3–74.4) and 46.7% (95% CI: 21.2–68.7). Esophageal resection was not required in 20 of 41 patients (49%) on this trial.ConclusionsThe long-term results of NRG Oncology Radiation Therapy Oncology Group 0246 demonstrate promising efficacy of a selective surgical resection strategy and suggest the need for larger randomized studies to further evaluate this organ-preserving approach. 相似文献